<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002982</url>
  </required_header>
  <id_info>
    <org_study_id>97-004</org_study_id>
    <secondary_id>CDR0000065505</secondary_id>
    <secondary_id>NCI-H97-1233</secondary_id>
    <nct_id>NCT00002982</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Trial of ICE Chemotherapy Followed by High Dose BEAM Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients &gt;= 60 Years Old With Refractory or Relapsed Intermediate Grade Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give&#xD;
      higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with peripheral stem cell transplantation works in treating older patients with refractory or&#xD;
      relapsed intermediate-grade non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the efficacy and toxic effects of carmustine/etoposide/melphalan (ICE)&#xD;
           chemotherapy followed by peripheral blood progenitor cell transplantation in patients&#xD;
           with refractory or relapsed intermediate grade non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Assess the ability of the ICE chemotherapy regimen, in conjunction with filgrastim, to&#xD;
           mobilize peripheral blood stem cells.&#xD;
&#xD;
      OUTLINE: This is a descriptive pilot study.&#xD;
&#xD;
      Patients receive 3 cycles of induction chemotherapy with ifosfamide, carboplatin, and&#xD;
      etoposide (ICE). Each cycle is given at least 14 days apart. Patients receive etoposide IV on&#xD;
      days 1 through 3. Carboplatin and ifosfamide with mercaptoethane sulfonate is given IV over&#xD;
      24 hours on day 2.&#xD;
&#xD;
      During cycles 1 and 2, patients receive filgrastim (G-CSF) SC every 6 hours beginning on day&#xD;
      1 and continuing until the desired absolute neutrophil count (ANC) is attained.&#xD;
&#xD;
      Patients receive at least 24 hours of rest before PBPC infusion on day 0.&#xD;
&#xD;
      Following cycle 3, G-CSF is given SC beginning on day 6 and continuing until completion of&#xD;
      PBPC collection. However, bone marrow will be harvested if an insufficient number of stem&#xD;
      cells are collected after 5 leukaphereses.&#xD;
&#xD;
      Patients with residual disease limited to 2 sites receive radiation therapy twice a day&#xD;
      within 2 weeks prior to high dose BEAM chemotherapy with carmustine, etoposide, cytarabine,&#xD;
      and melphalan.&#xD;
&#xD;
      Patients receive carmustine IV on day -7. Etoposide and cytarabine are given IV every 12&#xD;
      hours on days -6 through -3. Melphalan is given IV on day -2.&#xD;
&#xD;
      G-CSF is administered every 12 hours beginning on day 1 and continuing until the desired ANC&#xD;
      is attained. If ANC is attenuated on day 21, patients undergo a repeat bone marrow biopsy and&#xD;
      receive filgrastim SC.&#xD;
&#xD;
      Patients are followed for 2 years posttransplant, then for 3 to 5 years at 4 month intervals&#xD;
      and every 6 months following the fifth posttransplant.&#xD;
&#xD;
      PROJECTED ACCRUAL: This study will accrue 30 patients for the duration of 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy in terms of 2-year disease-free survival</measure>
  </secondary_outcome>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Primary refractory intermediate grade non-Hodgkin's lymphoma (NHL) OR&#xD;
&#xD;
          -  Untreated relapsed intermediate grade NHL with no more than 1 extranodal site of&#xD;
             disease&#xD;
&#xD;
          -  Biopsy proven relapse of diffuse large cell, diffuse mixed cell, diffuse small cleaved&#xD;
             cell (excluding mantle cell lymphoma), follicular large cell, anaplastic large cell or&#xD;
             immunoblastic NHL in recently attained complete response patients&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  60 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky at least 80%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL unless there is a history of Gilbert's disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No history of chronic renal insufficiency&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL or if greater than 1.5 mg/dL, then creatinine&#xD;
             clearance must be at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable angina or cardiac arrhythmias other than chronic atrial fibrillation&#xD;
&#xD;
          -  Normal cardiac function required; MUGA scan or stress ECG ejection fraction at least&#xD;
             50% without significant wall motion abnormalities&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Adequate pulmonary function defined as DLCO at least 50% of predicted value when&#xD;
             corrected for patients hemoglobin and alveolar ventilation&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No medical illness unrelated to intermediate grade Non-Hodgkin's Lymphoma&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No history of malignancy other than curatively treated cutaneous basal cell carcinoma;&#xD;
             carcinoma in situ of the cervix; axillary node negative breast cancer without prior&#xD;
             chemotherapy and disease free for more than 2 years; or prostate cancer with surgery&#xD;
             alone and disease free for more than 2 years&#xD;
&#xD;
          -  No lymphoblastic lymphoma, small noncleaved cell lymphoma, CNS lymphoma or CNS relapse&#xD;
             of lymphoma&#xD;
&#xD;
          -  Not HIV, HBV, and HCV positive&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Concurrent enrollment in MSKCC protocol 96-17a allowed&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Moskowitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

